About this source
- Kind
- Research
- Design
- Human clinical trial, RCT
- Population
- Subgroups of adults with primary mitochondrial myopathy from the MMPOWER-3 trial
- Primary or secondary
- primary
- Peer review
- peer reviewed
- Retraction status
- None known
- Date checked
- 14 November 2026
Limitations
Post hoc subgroup analysis after a trial that did not meet its primary endpoint. It generates hypotheses and does not confirm a benefit. The abstract gives no total sample size. Abstract read via Europe PMC; full text not read.
Cited in
MMPOWER-3 subgroup analysis
Elamipretide · Research finding
Preliminary
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.